Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | mCRPC: cabazitaxel re-challenge

Alison Birtle, MBBS, MRCP, FRCR, MD, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK, discusses cabazitaxel re-challenge therapy in metastatic castrate-resistant prostate cancer (mCRPC) patients. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.